Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chongqing Sintaho Pharmaceutical
Chongqing, Chongqing, Chinaen.sintaho.com ↗
- Ownership
- Private
- Employees
- ~260
- Development stage
- Other
01
Overview
Sintaho is an established supplier of GMP-compliant cytotoxic and non-cytotoxic APIs including docetaxel, paclitaxel, carfilzomib, tirbanibulin, and eribulin, with approvals and DMFs in >30 countries including China, US, EU. Clinical results for these molecules are referenced for approved/marketed products only, not for Sintaho-specific clinical development.
- Therapeutic areas
- OncologyNeurologyMetabolic Disorders
- Modalities
- Small moleculePolypeptideAntibody-drug conjugate (ADC)
- Industry
- Contract Manufacturing Organization
02
Partnerships
Not explicitly listed; extensive partnerships reported with global pharma companies for supply chain/API production. Linked in global supply chain network, serving US, EU, China, etc.
Beyond the preview
Go deeper on Chongqing Sintaho Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Sintaho Pharmaceutical.